针对所有临床病症的安慰剂干预措施。
Placebo interventions for all clinical conditions.
作者信息
Hróbjartsson Asbjørn, Gøtzsche Peter C
机构信息
The Nordic Cochrane Centre, Rigshospitalet, Blegdamsvej 9, 3343, Copenhagen, Denmark, 2100.
出版信息
Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD003974. doi: 10.1002/14651858.CD003974.pub3.
BACKGROUND
Placebo interventions are often claimed to substantially improve patient-reported and observer-reported outcomes in many clinical conditions, but most reports on effects of placebos are based on studies that have not randomised patients to placebo or no treatment. Two previous versions of this review from 2001 and 2004 found that placebo interventions in general did not have clinically important effects, but that there were possible beneficial effects on patient-reported outcomes, especially pain. Since then several relevant trials have been published.
OBJECTIVES
Our primary aims were to assess the effect of placebo interventions in general across all clinical conditions, and to investigate the effects of placebo interventions on specific clinical conditions. Our secondary aims were to assess whether the effect of placebo treatments differed for patient-reported and observer-reported outcomes, and to explore other reasons for variations in effect.
SEARCH STRATEGY
We searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library Issue 4, 2007), MEDLINE (1966 to March 2008), EMBASE (1980 to March 2008), PsycINFO (1887 to March 2008) and Biological Abstracts (1986 to March 2008). We contacted experts on placebo research, and read references in the included trials.
SELECTION CRITERIA
We included randomised placebo trials with a no-treatment control group investigating any health problem.
DATA COLLECTION AND ANALYSIS
Two authors independently assessed trial quality and extracted data. We contacted study authors for additional information. Trials with binary data were summarised using relative risk (a value of less than 1 indicates a beneficial effect of placebo), and trials with continuous outcomes were summarised using standardised mean difference (a negative value indicates a beneficial effect of placebo).
MAIN RESULTS
Outcome data were available in 202 out of 234 included trials, investigating 60 clinical conditions. We regarded the risk of bias as low in only 16 trials (8%), five of which had binary outcomes.In 44 studies with binary outcomes (6041 patients), there was moderate heterogeneity (P < 0.001; I(2) 45%) but no clear difference in effects between small and large trials (symmetrical funnel plot). The overall pooled effect of placebo was a relative risk of 0.93 (95% confidence interval (CI) 0.88 to 0.99). The pooled relative risk for patient-reported outcomes was 0.93 (95% CI 0.86 to 1.00) and for observer-reported outcomes 0.93 (95% CI 0.85 to 1.02). We found no statistically significant effect of placebo interventions in four clinical conditions that had been investigated in three trials or more: pain, nausea, smoking, and depression, but confidence intervals were wide. The effect on pain varied considerably, even among trials with low risk of bias.In 158 trials with continuous outcomes (10,525 patients), there was moderate heterogeneity (P < 0.001; I(2) 42%), and considerable variation in effects between small and large trials (asymmetrical funnel plot). It is therefore a questionable procedure to pool all the trials, and we did so mainly as a basis for exploring causes for heterogeneity. We found an overall effect of placebo treatments, standardised mean difference (SMD) -0.23 (95% CI -0.28 to -0.17). The SMD for patient-reported outcomes was -0.26 (95% CI -0.32 to -0.19), and for observer-reported outcomes, SMD -0.13 (95% CI -0.24 to -0.02). We found an effect on pain, SMD -0.28 (95% CI -0.36 to -0.19)); nausea, SMD -0.25 (-0.46 to -0.04)), asthma (-0.35 (-0.70 to -0.01)), and phobia (SMD -0.63 (95% CI -1.17 to -0.08)). The effect on pain was very variable, also among trials with low risk of bias. Four similarly-designed acupuncture trials conducted by an overlapping group of authors reported large effects (SMD -0.68 (-0.85 to -0.50)) whereas three other pain trials reported low or no effect (SMD -0.13 (-0.28 to 0.03)). The pooled effect on nausea was small, but consistent. The effects on phobia and asthma were very uncertain due to high risk of bias. There was no statistically significant effect of placebo interventions in the seven other clinical conditions investigated in three trials or more: smoking, dementia, depression, obesity, hypertension, insomnia and anxiety, but confidence intervals were wide.Meta-regression analyses showed that larger effects of placebo interventions were associated with physical placebo interventions (e.g. sham acupuncture), patient-involved outcomes (patient-reported outcomes and observer-reported outcomes involving patient cooperation), small trials, and trials with the explicit purpose of studying placebo. Larger effects of placebo were also found in trials that did not inform patients about the possible placebo intervention.
AUTHORS' CONCLUSIONS: We did not find that placebo interventions have important clinical effects in general. However, in certain settings placebo interventions can influence patient-reported outcomes, especially pain and nausea, though it is difficult to distinguish patient-reported effects of placebo from biased reporting. The effect on pain varied, even among trials with low risk of bias, from negligible to clinically important. Variations in the effect of placebo were partly explained by variations in how trials were conducted and how patients were informed.
背景
在许多临床病症中,安慰剂干预措施常被宣称能显著改善患者报告和观察者报告的结果,但大多数关于安慰剂效应的报告所基于的研究,并未将患者随机分为接受安慰剂或不接受治疗两组。2001年和2004年该综述的前两个版本发现,一般而言安慰剂干预并无重要临床效果,但对患者报告的结果可能存在有益影响,尤其是疼痛方面。自那时起,已发表了多项相关试验。
目的
我们的主要目的是评估安慰剂干预在所有临床病症中的总体效果,并研究安慰剂干预对特定临床病症的影响。次要目的是评估安慰剂治疗在患者报告结果和观察者报告结果方面的效果是否存在差异,并探究效应差异的其他原因。
检索策略
我们检索了Cochrane对照试验中心注册库(CENTRAL,《Cochrane图书馆》2007年第4期)、MEDLINE(1966年至2008年3月)、EMBASE(1980年至2008年3月)、PsycINFO(1887年至2008年3月)以及生物学文摘数据库(1986年至2008年3月)。我们联系了安慰剂研究领域的专家,并阅读了纳入试验中的参考文献。
选择标准
我们纳入了设有不治疗对照组、针对任何健康问题进行研究的随机安慰剂试验。
数据收集与分析
两位作者独立评估试验质量并提取数据。我们联系研究作者获取更多信息。对于二元数据的试验采用相对危险度进行汇总(小于1的值表明安慰剂具有有益效果),对于连续性结果的试验采用标准化均数差进行汇总(负值表明安慰剂具有有益效果)。
主要结果
在纳入的234项试验中的202项中可获取结果数据,这些试验涉及60种临床病症。我们仅在16项试验(8%)中认为偏倚风险较低,其中5项试验有二元结果。在44项有二元结果的研究(6041例患者)中,存在中度异质性(P < 0.001;I² 45%),但大小试验之间的效应无明显差异(漏斗图对称)。安慰剂的总体合并效应为相对危险度0.93(95%置信区间(CI)0.88至0.99)。患者报告结果的合并相对危险度为0.93(95% CI 0.86至1.00),观察者报告结果为0.93(95% CI 0.85至1.02)。我们发现在三项或更多试验中研究过的四种临床病症(疼痛、恶心、吸烟和抑郁)中,安慰剂干预无统计学显著效应,但置信区间较宽。即便在偏倚风险较低的试验中,对疼痛的效应也差异很大。在158项有连续性结果的试验(10525例患者)中,存在中度异质性(P < 0.001;I² 42%),大小试验之间的效应差异较大(漏斗图不对称)。因此,将所有试验进行汇总这一做法存在问题,我们这样做主要是为了探究异质性的原因。我们发现安慰剂治疗的总体效应为标准化均数差(SMD)-0.23(95% CI -0.28至-0.17)。患者报告结果的SMD为-0.26(95% CI -0.32至-0.19),观察者报告结果的SMD为-0.13(95% CI -0.24至-0.02)。我们发现对疼痛有效应(SMD -0.28(95% CI -0.36至-0.19));对恶心有效应(SMD -0.25(-0.46至-缉拿)),对哮喘(-0.35(-0.70至-0.01))和恐惧症(SMD -0.63(95% CI -1.17至-0.08))有效应。即便在偏倚风险较低的试验中,对疼痛的效应也变化很大。一组重叠作者进行过的四项设计相似的针灸试验报告了较大效应(SMD -0.68(-0.85至-0.50)),而其他三项疼痛试验报告效应较低或无效应(SMD -0.13(-0.28至0.03))。对恶心的合并效应较小,但具有一致性。由于偏倚风险较高,对恐惧症和哮喘的效应非常不确定。在三项或更多试验中研究过并且安慰剂干预无统计学显著效应的其他七种临床病症(吸烟、痴呆、抑郁、肥胖、高血压、失眠和焦虑)中,置信区间较宽。Meta回归分析表明,安慰剂干预的较大效应与物理安慰剂干预(如假针灸)、患者参与的结果(患者报告结果以及涉及患者合作的观察者报告结果)、小型试验以及以研究安慰剂为明确目的的试验相关。在未告知患者可能存在安慰剂干预的试验中也发现了较大的安慰剂效应。
作者结论
我们并未发现安慰剂干预总体上具有重要临床效果。然而,在某些情况下,安慰剂干预可影响患者报告的结果,尤其是疼痛和恶心,尽管难以将安慰剂的患者报告效应与有偏倚的报告区分开来。即便在偏倚风险较低的试验中,对疼痛的效应也有所不同,从可忽略不计到具有临床重要性。安慰剂效应的差异部分可由试验实施方式以及告知患者方式的差异来解释。